Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H24N.CH3O4S |
Molecular Weight | 389.508 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COS([O-])(=O)=O.C[N+]1(C)CCC(CC1)=C(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=BREMLQBSKCSNNH-UHFFFAOYSA-M
InChI=1S/C20H24N.CH4O4S/c1-21(2)15-13-19(14-16-21)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18;1-5-6(2,3)4/h3-12H,13-16H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
DescriptionSources: http://pubs.acs.org/doi/abs/10.1021/ja01154a556
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01154a556
Diphemanil methylsulfate (Prantal), a quarternary amine, is a highly specific parasympathetic blocking agent.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01154a556
Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/diphemanil-methylsulfate.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PRANTAL Approved UseDiphemanil Methylsulfate is used for Peptic ulcer, Gastric hyperacidity, Hypermotility in gastritis, Pylorospasm, Hyperhidrosis and other conditions. |
|||
Primary | PRANTAL Approved UseDiphemanil Methylsulfate is used for Peptic ulcer, Gastric hyperacidity, Hypermotility in gastritis, Pylorospasm, Hyperhidrosis and other conditions. |
|||
Primary | PRANTAL Approved UseDiphemanil Methylsulfate is used for Peptic ulcer, Gastric hyperacidity, Hypermotility in gastritis, Pylorospasm, Hyperhidrosis and other conditions. |
|||
Primary | PRANTAL Approved UseDiphemanil Methylsulfate is used for Peptic ulcer, Gastric hyperacidity, Hypermotility in gastritis, Pylorospasm, Hyperhidrosis and other conditions. |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1623915/ |
unknown, oral |
DIPHEMANIL unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
8.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8087216/ |
3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
DIPHEMANIL plasma | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
2 mg single, respiratory Highest studied dose |
unhealthy, 25 years (range: 19-40 years) n = 20 Health Status: unhealthy Condition: asymptomatic asthma Age Group: 25 years (range: 19-40 years) Population Size: 20 Sources: |
|
2 % single, topical Highest studied dose |
unhealthy, 27-66 years n = 15 Health Status: unhealthy Condition: Frey's syndrome Age Group: 27-66 years Sex: M+F Population Size: 15 Sources: |
Other AEs: Dry mouth... |
250 mg single, oral |
healthy, 30.8 years (range: 26 -42 years) n = 6 Health Status: healthy Age Group: 30.8 years (range: 26 -42 years) Sex: M Population Size: 6 Sources: |
Other AEs: Dry mouth, Headache... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dry mouth | 2 patients | 2 % single, topical Highest studied dose |
unhealthy, 27-66 years n = 15 Health Status: unhealthy Condition: Frey's syndrome Age Group: 27-66 years Sex: M+F Population Size: 15 Sources: |
Dry mouth | 1 patient | 250 mg single, oral |
healthy, 30.8 years (range: 26 -42 years) n = 6 Health Status: healthy Age Group: 30.8 years (range: 26 -42 years) Sex: M Population Size: 6 Sources: |
Headache | 1 patient | 250 mg single, oral |
healthy, 30.8 years (range: 26 -42 years) n = 6 Health Status: healthy Age Group: 30.8 years (range: 26 -42 years) Sex: M Population Size: 6 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Prantal in the treatment of hyperhidrosis. | 1951 Oct |
|
Prantal in dermatology. | 1952 May |
|
Effect of inhaled diphemanil methylsulfate, a parasympatholytic agent, on histamine induced bronchoconstriction in asymptomatic asthmatics. | 1984 Jan |
|
Treatment of Frey's syndrome with topical 2% diphemanil methylsulfate (Prantal): a double-blind evaluation of 15 patients. | 1990 Jun |
Patents
Sample Use Guides
Diphenylmethane methylsulfate was prescribed for the treatment of hyperhidrosis in a divided daily dosage of 200—400 mg.
Fifteen patients with severe gustatory sweating after total parotidectomy and facial nerve preservation were alternatively treated with topically applied placebo and topically applied 2% diphemanil methylsulfate.
2 mg dose of diphemanil, administered by oral inhalation 20 minutes before histamine challenge, is ineffective in protecting against induced bronchospasm in asymptomatic adult asthmatics.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 310.201
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
||
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
62-97-5
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
DIPHEMANIL METILSULFATE
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
41725
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
SUB07208MIG
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
W2ZG23MGYI
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
DTXSID9022948
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
6126
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
59782
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
C65419
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
100000082877
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201340
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
DB00729
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
C028209
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
342
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | |||
|
m4606
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
23364
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
200-552-4
Created by
admin on Fri Dec 15 16:00:18 GMT 2023 , Edited by admin on Fri Dec 15 16:00:18 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD